NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York. A live webcast of this presentation may be ...

NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Bank of America Securities 2024 Health Care Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Tuesday, May 14, 2024 at 4:20 p.m. PT in Las Vegas. A live webcast of this pre ...

NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. ("Dianthus"), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on April 1, 2024, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of ...

NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus"), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement t ...

NEW YORK and WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that members of the Company's senior management team will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024, at 10:30 a.m. EST in New York City. A live webcast of this presentation ...

MGTA-117 Targeted Conditioning - Additional clinical evidence of Proof-of-Mechanism is expected in Q4 2022[6] - Advancement into Transplant-Eligible Patients is anticipated in H1 2023[6] - MGTA-117 has the potential to reduce patient exposure to chemotherapy agents, reduce relapse, and extend survival while minimizing toxicities in blood cancer patients[14] - MGTA-117 aims to eliminate the use of busulfan in HSC gene therapy patients[15] - MGTA-117 was rapidly cleared and no longer measurable 48 hours post-dosing in Cohort 1[45] MGTA-145 Stem Cell Mobilization - Stem cell mobilization data in Sickle Cell Disease is expected in December 2022[6] - In a Phase 2 trial for Multiple Myeloma, 88% of patients achieved 2 million cells/kg, and 70% achieved 4 million cells/kg with MGTA-145[72] - In the same trial, engraftment was observed in 100% of patients (19/19)[72] CD45-ADC Targeted Conditioning - Advancement of IND-enabling studies is planned for 2023[6] - Preclinical data shows a single dose of CD45-targeted ADC depleted 90% of stem cells and 90% of immune cells in NHPs[68] Financial Status - The company projects its cash runway will extend into Q2 2024[2, 6]

| --- | --- | --- | --- | --- | --- | --- | |-----------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Conference (January 2022) | | | | | | | | J.P. Morgan Healthcare | | | | | | | | (NASDAQ:MGTA) | | | | | | | Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal secu ...

| --- | --- | --- | --- | --- | --- | |------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Magenta Therapeutics | | | | | | | Corporate Presentation | | | | | | | August 2021 | | | | | | | (NASDAQ:MGTA) | | | | | | Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express ...

| --- | --- | --- | --- | --- | --- | |------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Magenta Therapeutics | | | | | | | Corporate Presentation | | | | | | | June 2021 | | | | | | | (NASDAQ:MGTA) | | | | | | Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express o ...